What Kern Pharma does

Kern Pharma is a Spanish pharmaceutical laboratory founded in 1999 and headquartered in Terrassa (Barcelona), operating as the primary pharmaceutical entity within the family-owned Grupo Indukern conglomerate controlled by the Díaz-Varela family. The company develops, manufactures, and markets generic medicinal products across therapeutic areas including analgesics, cardiovascular, central nervous system, antiinfectives, oncology, respiratory, urology, and musculoskeletal treatments, with a portfolio of over 230 products in more than 400 presentations that covers approximately 90% of Spanish prescription needs. Operations are vertically integrated: an in-house chemical plant synthesizes active pharmaceutical ingredients (APIs), formulation laboratories develop finished products, GMP-certified production plants manufacture them, and a 20,000-pallet automated logistics center distributes output, supporting annual production exceeding 100 million units.

The business is organized into five divisions: Generic Drugs (the core), Consumer (pharmacy-recommended products), Biologics (biosimilar medicines), Gynea (women's health, including the Gynefert fertility and Gestagyn prenatal lines, acquired through the 2014 Gynea Laboratorios acquisition), and Finisher (sports nutrition supplements). A sixth line, Production to Third Parties, offers contract manufacturing services to large pharmaceutical companies. Distribution runs through pharmacy and hospital channels in Spain, via the wholly-owned Pharmakern Portugal subsidiary in Carnaxide (Lisbon), and across more than 25 international markets where Kern Pharma holds local GMP approvals. Customers are primarily healthcare professionals (prescribers and pharmacists) and patients; secondary B2B revenue comes from hospital procurement and contract manufacturing clients. Marketing combines field sales, scientific information dissemination to professionals, content marketing via the company blog, broad social media presence, and the Equipo Ciclista Kern Pharma professional cycling team sponsorship as a brand-building asset.

The company is privately held under Grupo Indukern with no public funding rounds disclosed, and reports no revenue. Certifications include EU GMP, GLP, and GDP; ISO 14001:2015 (TÜV Rheinland); and EcoVadis sustainability rating. Raúl Díaz-Varela serves as founder, president, and CEO. Current headcount is disclosed only as a 501-1000 band, with 104 employees at founding in 1999.

Name

Kern Pharma

Legal name

Kern Pharma S.L

Website

https://kernpharma.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Kern Pharma is a privately held Spanish pharmaceutical laboratory founded in 1999 in Terrassa (Barcelona), part of the Díaz-Varela family's Grupo Indukern. It develops, manufactures, and markets generic medicines, biosimilars, women's health (Gynea), and sports nutrition (Finisher) products, serving healthcare professionals, patients, hospitals, and large pharma clients via contract manufacturing across 25+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Active pharmaceutical ingredients
• Contract manufacturing
• Consumer health products

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Products: Development, manufacturing and marketing of generic medicinal products across therapeutic areas including analgesics, cardiovascular, CNS, antiinfectives, and oncology. Products are distributed through pharmacy and hospital channels.
2. Consumer Health Products: Consumer division focused on marketing products for pharmaceutical recommendation, including consumer health and personal care products.
3. Biosimilar Medicines (Biologics): Division focused on biosimilar medicines, developing and commercializing biosimilar pharmaceutical products.
4. Women's Health Products (Gynea): Gynea brand markets women's health products across all life stages, including contraceptives, menopause treatments, and intimate health.
5. Sports Nutrition (Finisher): Finisher brand offers sports health and nutrition products including protein supplements, BCAA, caffeine, and multivitamins for fitness consumers.
6. Contract Manufacturing (Production to Third Parties): Kern Pharma manufactures products for large pharmaceutical companies leveraging its reliability, competitiveness and experience in transferring productions. Manufacturing capabilities include GMP-certified production plants and chemical synthesis.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Kern Pharma develops, manufactures, and markets generic medicinal products, biosimilar medicines, consumer health products, women's health products under the Gynea brand, and sports nutrition products under the Finisher brand. The company operates vertically integrated GMP-certified production plants, an API synthesis chemical plant, analytical laboratories, and automated logistics, producing over 100 million units annually of more than 230 products in 400+ presentations. It also offers contract manufacturing services to large pharmaceutical companies through its Production to Third Parties business.

Product overview

Kern Pharma is a pharmaceutical company operating as a single unified business rather than a platform-plus-modules architecture. The company has five main divisions: Generic Drugs (core business with over 230 products in 400+ presentations covering 90% of prescription needs), Consumer (OTC products for pharmaceutical recommendation), Biologics (biosimilar medicines), Gynea (women's health sub-brand including Gynefert fertility products and Gestagyn prenatal supplements), and Finisher (sports nutrition sub-brand with protein, vitamin, and supplement products). Additionally, the company offers contract manufacturing services under Production to Third Parties. Kern Pharma's portfolio spans therapeutic areas including analgesics, cardiovascular, CNS, antiinfectives, oncology, respiratory, urology, and musculoskeletal treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Gynea: Women's health brand offering a wide portfolio of products aimed at improving women's health at all stages of their lives.
• Finisher

Products and services

• Generic Drugs Division Core division developing, manufacturing, and marketing generic medicinal products across therapeutic areas including analgesics, cardiovascular, CNS, antiinfectives, and oncology. Distributed through Spanish and Portuguese pharmacy and hospital channels.
• Consumer Health Division Division focused on marketing consumer health and personal care products recommended by pharmacists through retail pharmacy channels.
• Biologics (Biosimilar Medicines) Division dedicated to developing and commercializing biosimilar medicines, providing biologic treatment alternatives in therapeutic areas where biosimilars are approved.
• Gynea (Women's Health Brand) Sub-brand marketing a wide portfolio of products aimed at improving women's health at all life stages, including contraceptives, fertility treatments (Gynefert), prenatal supplements (Gestagyn), menopause treatments, and intimate health products.
• Finisher (Sports Nutrition Brand) Sports health and nutrition brand offering products including Triple Magnesium, Whey Protein, Vegan Protein, BCA, Intensity, Endurance, Recovery, Caffeine, energy bars, protein bars, multivitamins and minerals, thermogenic, and mineral salts plus vitamins for fitness consumers.
• Production to Third Parties (Contract Manufacturing) Contract manufacturing services offering GMP-certified production plant capacity and chemical synthesis (API manufacturing) to large pharmaceutical companies for finished-dose and active ingredient production.
• CondroStop (Joint Support Product) Musculoskeletal health product for joint support.

Quantifiable outcome

• Portfolio covers 90% of prescription needs in Spain with 230+ products in 400+ presentations
• +1 more outcomes

Named customers1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• EcovadiscoreStrategic or Co-development PartnerKern Pharma partnered with Ecovadis to implement a supplier evaluation program for its supply chain. The objective is to ensure that suppliers work to standards similar to Kern Pharma in employment practices and human rights, environment, ethical business practices, and responsible procurement.
• Pharmakern Portugal – Produtos Farmacêuticos, Sociedade Unipessoal LdacoreChannel Partner/ Reseller/ DistributorPharmakern Portugal is Kern Pharma's subsidiary and distribution partner for the Portuguese market, operating from offices in Carnaxide, Lisbon. The subsidiary handles commercial distribution and regulatory affairs in Portugal.
• Special Employment Centres (8 CEE partners)minorOthersKern Pharma collaborates with eight Special Employment Centres (Centros Especiales de Empleo) that employ people with disabilities to support the company's daily operations through gardening, cleaning, and other tasks. These partnerships contribute to social inclusion and local community development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cinfa: Spanish family-owned generic pharmaceutical manufacturer with a broad prescription portfolio and OTC consumer health lines. Directly competes with Kern Pharma in Spanish pharmacy channels with similar scale, vertical integration, and diversification into biosimilars and consumer brands.
• Laboratorios Normon: Spanish generics specialist headquartered in Madrid with a broad portfolio of generic prescription medicines distributed through Spanish pharmacies. A close Iberian generic competitor with comparable scale and channel focus.
• Stada Arzneimittel: European generic and consumer healthcare leader with significant presence in Spain through Stada Spain. Directly comparable in generic portfolio breadth, biosimilar strategy, and consumer health sub-brands across European pharmacy channels.
• Ratiopharm (Teva): German generic pharmaceutical brand under Teva with a comprehensive prescription portfolio across Europe. Comparable in product breadth, pharmacy distribution model, and focus on affordable generic medicines for primary care.
• Apotex: Canadian-based generic pharmaceutical manufacturer with growing European presence and biosimilar capabilities. Comparable mid-sized generic player competing in international tenders and contract manufacturing markets.
• Laboratorios Salvat: Spanish family-owned pharmaceutical company focused on specialty generics, ENT, and biosimilar development. Comparable Iberian pharma peer with similar family ownership structure, scale, and biosimilar/biotech ambitions.

Regional players

• Almirall: Barcelona-based pharmaceutical company with a mix of branded dermatology and generic prescription medicines, plus consumer health. Comparable Spanish pharma peer operating through similar pharmacy and hospital channels with broader international presence.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with significant operations across Europe including Spain and Portugal. Competes with Kern Pharma on global generic tenders and biosimilars, though at vastly greater scale and broader portfolio.
• Viatris: Global pharmaceutical company formed from the Mylan-Upjohn merger with a major generic and biosimilar franchise. Competes with Kern Pharma in European generics and biosimilars tenders, including through its strong Spanish commercial presence.
• Sandoz (Novartis): Global leader in generic and biosimilar medicines, now positioned for separation from Novartis. Overlaps directly with Kern Pharma's generics and biosimilars strategy across European markets with much larger scale and R&D investment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Kernpharma
• YouTubeyoutube.com/channel/UCugMoAlCdxv2ZtATiRaQuIA
• Facebookfacebook.com/kernpharma
• LinkedInlinkedin.com/company/kern-pharma
• Instagraminstagram.com/kern_pharma/?hl=es
• TikToktiktok.com/@kernpharma

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kern Pharma